Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2025-02-12 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Illuccix Approved in the United Kingdom 3 pages 189.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 13 February 2025, announcing the approval of their prostate cancer imaging agent Illuccix® by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). The content focuses on the regulatory approval, product details, distribution plans, and forward-looking statements about the product and company. There are no financial statements, detailed financial performance data, or comprehensive management discussion of financial results. The document is a corporate announcement about a regulatory milestone and product commercialization, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. Therefore, the document best fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2025-02-12 English
Telix 2024 Full Year Results and Investor Webcast/Call 2 pages 144.8KB
Report Publication Announcement Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 11 February 2024. It notifies the market and investors about the upcoming release of the company's full year results and Australian Annual Report for the period ended 31 December 2024, scheduled for 20 February 2025. It also announces an investor webcast and conference call to discuss these results. The document does not contain the actual full year results or the annual report itself, but rather serves as a notification of their forthcoming release. The document length is 7475 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the "Menu vs Meal" rule, this document should be classified as a Report Publication Announcement (RPA) rather than the Annual Report (10-K) or Earnings Release (ER).
2025-02-10 English
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2025-01-31 English
Telix Completes Acquisition of Tx Assets, Biologics Platform 4 pages 165.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 31 January 2025, detailing the completion of an acquisition of next-generation therapeutic assets and a biologics technology platform from ImaginAb, Inc. It includes transaction details such as upfront consideration, equity issuance, deferred payments, and milestone payments. The content focuses on the acquisition transaction, strategic rationale, and operational integration, without presenting financial statements, earnings data, or regulatory certifications. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is a corporate announcement about a capital transaction (acquisition) and financing terms, which fits the Capital/Financing Update category. The document length (12,614 characters) and detailed transaction terms support this classification rather than a brief report publication announcement or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-01-30 English
Application for quotation of securities - TLX 6 pages 19.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the number and type of securities to be quoted, references previous announcements (Appendix 3B), and provides information about issued capital following the quotation. This type of document is a regulatory announcement related to capital market activities, specifically the listing or quotation of securities. It is not a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, which cover new share issues and related capital changes.
2025-01-30 English
Cleansing Notice 1 page 118.7KB
Share Issue/Capital Change Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001, referencing the issuance of shares as consideration for an acquisition. It is a formal announcement related to share issuance and compliance with disclosure requirements. The document is short (1425 characters) and does not contain financial statements or detailed financial data. It is not a full report but a regulatory announcement about share issuance and compliance. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2025-01-30 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.